Upgrades

Maintain BUY ratings on with a revised TP at Rs 2,780.

Maintain BUY ratings on Nestle India with a revised TP 1,340

Maintain BUY ratings on DOMS with a revised TP 3,110 per share

The recent reduction in GST rates from 28% to 18% across most segments in the auto sector may inject fresh demand momentum. This is in addition to the recent rationalisation of personal income tax slabs, interest rate cuts and the upcoming Pay Commission revisions.

We value the stock at 9x FY27E EV/EBITDA, arriving at a Target Price of Rs 1,560/share, implying an upside potential of 20% from the CMP.

LTF began FY26 on a stable footing, despite ongoing asset quality challenges in the MFI industry (more residual in nature), unsecured business loans and micro-LAP.

Despite a tough economic environment, Novelis delivered steady results. Also, to a cost reduction programme. However, Novelis faces tariff exposure on imports and is actively pursuing mitigation measures. Considering these factors, we retain our HOLD...

*over or under performance to benchmark index Zydus Lifesciences Ltd (Zydus) is one of India's leading, vertically integrated pharmaceutical companies. It operates across the value chain, from manufacturing finished dosages to active pharmaceutical ingredients, as well as animal healthcare and wellness products. Zydus' revenue increased 5.9% YoY to Rs. 6,574cr in Q1FY26 driven by 6.5% YoY...

Zydus Wellness Limited (ZWL) has acquired 100% stake in Comfort Click Ltd (CCL), which operates in UK and major European markets. This marks ZWL’s first overseas acquisition and its entry into the Vitamins, Minerals and Supplements (VMS) segment.

ICICIB reported some moderation in credit growth at ~12% YoY in 1Q, mainly due to slower growth in retail loans (incl mortgages and unsecured loans) and demand remaining slack in the corporate portfolio.